Challenges and solutions to superior chimeric antigen receptor‐T design and deployment for B‐cell lymphomas
British Journal of Haematology · 2023
DOI: 10.1111/bjh.19001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Jenny Gao und 2 weiteren Autor:innen. Beteiligte Einrichtung: RNA Therapeutics Institute, UMass Chan Medical School, Worcester, Massachusetts, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Antibodies, Bispecific, Lymphoma, B-Cell, Lymphoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Center for Clinical and Translational Science, University of Massachusetts.
Abstract (Originalsprache)
Chimeric antigen receptor‐T (CAR‐T) therapies represent a major breakthrough in cancer medicine, given the ex vivo‐based technology that harnesses the power of one's own immune system. These therapeutics have demonstrated remarkable success for relapsed/refractory B‐cell lymphomas. Although more than a decade has passed since the initial introduction of CAR‐T therapeutics for patients with leukaemia and lymphoma, there is still significant debate as to where CAR‐T therapeutics fit into the management paradigm, as consensus guidelines are limited. Competing interventions deployed in subsequent lines of therapy for aggressive lymphoma include novel targeted agents, bispecific antibodies, and time‐honoured stem cell transplant. In this focused review, we discuss the major obstacles to advancing the therapeutic reach for CAR‐T products in early lines of therapy. Such barriers include antigen escape, “cold” tumour microenvironments, host inflammation and CAR‐T cell exhaustion. We highlight solutions including point‐of‐care CAR‐T manufacturing and early T lymphopheresis. We review the evidence basis for early CAR‐T deployment for B‐cell lymphomas in light of the recent Food and Drug Administration (FDA) approval of three first‐in‐class anti‐CD3/CD20 bispecific antibodies—mosunetuzumab, epcoritamab and glofitamab. We propose practical recommendations for 2024.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RNA Therapeutics Institute, UMass Chan Medical School, Worcester, Massachusetts, USA.
- Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA.
- Division of Hematology/Oncology, Department of Medicine, UMass Memorial Medical Center, Center for Clinical and Translational Science, UMass Chan Medical School, Worcester, Massachusetts, USA.
ORCID-Profile: Shyam A Patel
Förderung
- NCATS NIH HHS
- Center for Clinical and Translational Science, University of Massachusetts
Zitieren
APA
Gao, J., Dahiya, S., & Patel, S. A. (2023). Challenges and solutions to superior chimeric antigen receptor‐T design and deployment for B‐cell lymphomas. British Journal of Haematology. https://doi.org/10.1111/bjh.19001
Vancouver
Gao J, Dahiya S, Patel SA. Challenges and solutions to superior chimeric antigen receptor‐T design and deployment for B‐cell lymphomas. British Journal of Haematology. 2023. doi:10.1111/bjh.19001
BibTeX
@article{Gao2023,
author = {Gao, Jenny and Dahiya, Saurabh and Patel, Shyam A},
title = {Challenges and solutions to superior chimeric antigen receptor‐T design and deployment for B‐cell lymphomas},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.19001}
}
EUVIMED